SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer
11 references·0 citing·53 second hop
Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer (2020)Cost-effectiveness of adding atezolizumab…Sustainability and affordability of cancer drugs: a novel pricing model (2018)Sustainability and affordabil…Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018)Global, regional, and nationa…The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC (2017)The effect of PD-L1 testing o…Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Recommendations for Conduct, …Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer (2015)Cost-Effectiveness of Pertuzu…Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)Updating Cost-Effectiveness —…Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting (2014)Investigation of Adverse-Even…Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves (2012)Enhanced secondary analysis o…Health state utilities for metastatic breast cancer (2006)Health state utilities for me…Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin (2001)Incremental cost-effectivenes…Net Health Benefits (1998)Net Health BenefitsA general parametric approach to the meta‐analysis of randomized clinical trials (1991)Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints (1998)CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (2010)Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data (2013)Choosing effect measures and computing estimates of effect (2019)IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves (2021)Cost-Effectiveness in Health and Medicine (1996)Quality of life and pharmacoeconomics in clinical trials (1996)EQ-SD: a measure of health status from the EuroQol Group (2001)Health-state utility values in breast cancer (2010)Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report (2016)Health state utilities in non–small cell lung cancer: An international study (2016)Willingness to Pay for a Quality-adjusted Life Year (2000)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research (2016)Economics and mental health: the current scenario (2020)Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer (2006)The Costs of Treating Breast Cancer in the US (2009)Understanding breast cancer survivors’ financial burden and distress after financial assistance (2020)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States (2016)Cost-Effectiveness in Health and Medicine (2016)Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions (2019)Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives (2020)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Methods for the Economic Evaluation of Health Care Programmes (2005)Understanding Costs of Care in the Operating Room (2018)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force (2022)Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations (2022)Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine (1994)META-ANALYSIS, DECISION ANALYSIS AND COST-EFFECTIVENESS ANALYSIS: METHODS FOR QUANTITATIVE SYNTHESIS IN MEDICINE. (1996)Health state utilities for non small cell lung cancer (2008)Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare (2018)Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma (2021)Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer (2021)Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016)Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016)Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018)Nature and mental health: An ecosystem service perspective (2019)Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 (2024)Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal (2024)Economic burden of cancer across the European Union: a population-based cost analysis (2013)Thresholds for the cost–effectiveness of interventions: alternative approaches (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe (2020)What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings (2020)Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021)Increasing risk II: Its economic consequences (1971)The Analytics of Uncertainty and Information (1992)The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies (1999)Representing uncertainty: the role of cost‐effectiveness acceptability curves (2001)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)
this work references cited by second hop

References

  • 2018Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 20174,192 cited
  • 2016Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses3,139 cited
  • 2012Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves2,587 cited
  • 2014Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold2,303 cited
  • 1998Net Health Benefits1,104 cited
  • 2006Health state utilities for metastatic breast cancer356 cited
  • 2015Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer115 cited
  • 2017The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC90 cited
  • 2018Sustainability and affordability of cancer drugs: a novel pricing model77 cited
  • 2014Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting59 cited
  • 2001Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin52 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work